Skip to main content
Premium Trial:

Request an Annual Quote

MolecularHealth, FDA Sign Five-Year Pact to Improve Drug Safety Assessment Software

Premium

MolecularHealth said this week that it has signed a five-year agreement with the US Food and Drug Administration under which the agency will "evaluate and refine" it's Molecular Analysis of Side Effects, or MASE, software, which supports mechanism-based drug safety assessment and prediction.

Specifically, the FDA's Center for Drug Evaluation and Research will work with MolecularHealth to add molecular and clinical endpoints of regulatory interest into MASE, along with information on patient populations, drug promiscuity, molecular modes of action, and mechanisms of disease.

MolecularHealth, which recently changed its name from Life Biosystems, launched the software-as-a-service offering last month (BI 1/20/2012).

The tool uses information about drug modes of action and the molecular implications of interacting treatments, co-morbidities, and genetic profiles to assess drug safety. It also enables the exploration and analysis of adverse event information from statistical and molecular perspectives and provides analytical and visualization tools to support the detection and validation of drug-related safety issues.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.